Pfizer
Axsome Plots New Fibromyalgia Trial After FDA Refuses Review of Former Pfizer Candidate
Axsome Therapeutics; esreboxetine; fibromyalgia; FDA; refusal to file; clinical trial; Pfizer; AXS-14; trial design; pain medicine
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo
FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote
Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707
Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development
Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials
CellCentric; Pfizer; multiple myeloma; Series C funding; inobrodib; p300/CBP inhibitor; oral drug; clinical trials; phase 2/3; accelerated approval
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027
Financial savings, Pfizer, Financial cost, Pfizer
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout
Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer
Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology